EUVIMEDEUVIMED entdecken
Crossref

Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor–associated acute interstitial nephritis

Coraima Claudia Nava Chavez iD, Sheila Bermejo, Victor Cuenca Narvaez, Omar Al Refai, Gurparneet Kaur Sohi, Callen Giesen, Lisa Kottschade, Svetomir N Markovic, Nelson Leung iD, John C Lieske, Maria Jose Soler iD, Sandra M Herrmann iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Coraima Claudia Nava Chavez und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Nephritis, Interstitial, Tumor Necrosis Factor-alpha, Chemokine CXCL9, Biomarkers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Mayo, CCaTS, Mayo Clinic.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although kidney biopsy remains the gold standard for diagnosing immune checkpoint inhibitors–associated acute interstitial nephritis (ICI-AIN), several promising urinary biomarkers have emerged as potential non-invasive diagnostics. Notably, recent studies have highlighted tumor necrosis factor alpha (TNF-α), CXC motif chemokine ligand 9 (CXCL-9) and others as potential biomarkers to help distinguish ICI-AIN from other causes of acute kidney injury (AKI). However, a direct systematic comparison between these two biomarkers in a cohort of patients undergoing immunotherapy has not been performed.

Methods

We prospectively enrolled a cohort of ICI-treated cancer patients who developed AKI (including both ICI-AIN and ICI-Non-AIN AKI), as well as those without AKI, referred to as the internal validation cohort. Urinary CXCL-9 and TNF-α were measured across all groups using the human Quantikine ELISA Kit. We externally validated our findings in a cohort of biopsy proven ICI-AIN patients from Spain, referred to as the external validation cohort.

Results

Urinary CXCL-9 levels were significantly higher in ICI-AIN patients from Mayo (n = 40) compared with those with ICI-Non-AIN AKI (n = 36) and ICI-treated patients without AKI (n = 16) (both P ≤ .0001); these findings were confirmed in the validation cohort from Spain (n = 19) with P-values of .0008 and <.0001, respectively. The area under the curve (AUC) for urinary CXCL-9 distinguishing ICI-AIN biopsy proven (combined from both cohorts, n = 45) from ICI-Non-AIN AKI was 0.83 (95% confidence interval 0.74–0.92), while for urinary TNF-α the AUC was 0.63 (0.51–0.75).

Conclusions

Increased urinary CXCL-9 was superior to TNF-α as a biomarker for the non-invasive diagnosis of ICI-AIN, even after prior corticosteroid exposure, highlighting its promise as clinical diagnostic tool.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nephritis, InterstitialTumor Necrosis Factor-alphaChemokine CXCL9BiomarkersImmune Checkpoint InhibitorsAcute Kidney InjuryNeoplasmsHumansFemaleMaleProspective StudiesMiddle AgedAgedPrognosisFollow-Up Studies

Stichwörter der Autor:innen

CXCL-9acute interstitial nephritisacute kidney injurybiomarkersimmune checkpoint inhibitors

Substanzen

Tumor Necrosis Factor-alphaChemokine CXCL9BiomarkersImmune Checkpoint InhibitorsCXCL9 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
  • Department of Nephrology, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Research, Barcelona, Spain.
  • Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
  • Department of Oncology, Mayo Clinic, Rochester, MN, USA.

ORCID-Profile: Coraima Claudia Nava Chavez, Nelson Leung, Maria Jose Soler, Sandra M Herrmann

Förderung

  • Mayo
  • CCaTS
  • Mayo Clinic
  • Instituto de Salud Carlos III

Zitieren

APA

Chavez, C. C. N., Bermejo, S., Narvaez, V. C., Refai, O. A., Sohi, G. K., Giesen, C., Kottschade, L., Markovic, S. N., Leung, N., Lieske, J. C., Soler, M. J., & Herrmann, S. M. (2026). Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor–associated acute interstitial nephritis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag016

Vancouver

Chavez CCN, Bermejo S, Narvaez VC, Refai OA, Sohi GK, Giesen C, et al. Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor–associated acute interstitial nephritis. Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag016

BibTeX
@article{Chavez2026,
  author = {Chavez, Coraima Claudia Nava and Bermejo, Sheila and Narvaez, Victor Cuenca and Refai, Omar Al and Sohi, Gurparneet Kaur and Giesen, Callen and Kottschade, Lisa and Markovic, Svetomir N and Leung, Nelson and Lieske, John C and Soler, Maria Jose and Herrmann, Sandra M},
  title = {Urinary CXCL-9 outperforms TNF-α for non-invasive diagnosis of immune checkpoint inhibitor–associated acute interstitial nephritis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag016}
}
Kostenlos starten →